NVO - Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy | Benzinga
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are likely to continue with Wegovy for more extended periods compared to older treatments commonly used.
Jorgensen emphasized the favorable effects observed among patients utilizing Wegovy, foreseeing these outcomes as incentives for continued usage. Although acknowledging it might be too early to definitively gauge, he expressed optimism about prolonged patient usage due to the encouraging impact experienced.
Citing an analysis of medical records and insurance ...